Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening

Gut

Volumn 62, Issue 5, 2013, Pages 727-734

  Goede, S Lucas ^a   Van Roon, Aafke H C ^a   Reijerink, Jacqueline C I Y ^b   Van Vuuren, Anneke J ^a   Lansdorp Vogelaar, Iris ^a   Habbema, J Dik F ^a   Kuipers, Ernst J ^a   Van Leerdam, Monique E ^a   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Association of Nationwide Screening South western Netherlands   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL EVALUATION; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; FECAL IMMUNOCHEMICAL TEST; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FECES; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84875844015     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301917     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7. (Pubitemid 26400242)
3. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002;50:29-32. (Pubitemid 34028299)
4. Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7. (Pubitemid 29128279)
5. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462-70.
6. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56:210-14.
7. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-25.
8. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. preventive services task force. Ann Intern Med 2008;149:638-58.
9. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-10.
10. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-8.
11. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90. (Pubitemid 351899018)
12. van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011;9:333-9.
13. Wilschut JA, Hol L, Dekker E, et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011;141:1648-55.-1.
14. Loeve F, Boer R, van Oortmarssen GJ, et al. The MISCANeCOLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999;32:13-33. (Pubitemid 29102594)
15. Loeve F, Boer R, van Ballegooijen M, et al. Final Report MISCANeCOLON Microsimulation Model For Colorectal Cancer: Report To The National Cancer Institute Project No. NO1-CN55186. Rotterdam, The Netherlands: Department of Public health, Erasmus University, 1998.
16. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, et al. A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer 2009;115:2410-19.
17. Loeve F, Boer R, Zauber AG, et al. National polyp study data: evidence for regression of adenomas. Int J Cancer 2004;111:633-9. (Pubitemid 39045333)
18. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006;107:1624-33. (Pubitemid 44546924)
19. Vogelaar I, van Ballegooijen M, Zauber AG. Model Profiler of the MISCAN-Colon Microsimulation Model For Colorectal Cancer. Department of Public health, Erasmus Medical Center. https://cisnet.flexkb.net/mp/pub/cisnet- colorectal-sloankettering-profile.pdf (accessed Dec 2011).
20. Morson B. President's address. The polypecancer sequence in the large bowel. Proc R Soc Med 1974;67:451-7.
21. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70.
22. Statistics Netherlands, Statline. http://statline.cbs.nl/StatWeb/default. aspx (accessed 14 Mar 2012).
23. Comprehensive Cancer Centre, Dutch cancer registry. http:// cijfersoverkanker.nl/(accessed 14 Mar 2012).
24. Lemmens V, van Steenbergen L, Janssen-Heijnen M, et al. Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta Oncol 2010;49:784-96.
25. Nagengast FM, Kaandorp CJ. Revised CBO guideline 'follow-up after polypectomy' (In Dutch). Ned Tijdschr Geneeskd 2001;145:2022-5.
26. Weller D, Coleman D, Robertson R, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer 2007;97:1601-5. (Pubitemid 350249359)
27. Steele RJ, McClements PL, Libby G, et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009;58:530-5.
28. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71. (Pubitemid 23131388)
29. Colquhoun P, Chen HC, Kim JI, et al. High compliance rates observed for follow up colonoscopy post polypectomy are achievable outside of clinical trials: efficacy of polypectomy is not reduced by low compliance for follow up. Colorectal Dis 2004;6:158-61. (Pubitemid 38660634)
30. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006;101:343-50. (Pubitemid 43381678)
31. Ness RM, Holmes AM, Klein R, et al. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999;94:1650-7. (Pubitemid 29260460)
32. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000;88:1294-303. (Pubitemid 30155164)
33. Zorzi M, Barca A, Falcini F, et al. Screening for colorectal cancer in Italy: 2005 survey. Epidemiol Prev 2007;31(2-3 Suppl 2):49-60.
34. van Roon AH, Wilschut JA, Van Leerdam ME, et al. Costs of guaiac versus immunochemical fecal occult blood testing within a randomized population-based colorectal cancer screening trial. Gastroenterology 2010;138:S189-90.
35. Dutch Health Care Authority, Law and regulations. http://www.nza.nl/ regelgeving/tarieven/(accessed 14 Mar 2012).
36. Dutch Health Care Insurance Board, Costs of Medications. http://www. medicijnkosten.nl/(accessed 14 Mar 2012).
37. Comprehensive Cancer Centre, Guidelines for Oncologic Treatments, http://www. oncoline.nl/(accessed 14 Mar 2012).
38. de Kok IM, Polder JJ, Habbema JD, et al. The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br J Cancer 2009;100:1240-4.
39. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009;101:1412-22.
40. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630-41.
41. Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost effectiveness in health and medicine. Pharmacoeconomics 1997;11:159-68. (Pubitemid 27086806)
42. Nakama H, Yamamoto M, Kamijo N, et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999;46:228-31. (Pubitemid 29154752)
43. Yamamoto M, Nakama H. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods. Hepatogastroenterology 2000;47:396-9. (Pubitemid 30216300)
44. Sobhani I, Alzahouri K, Ghout I, et al. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Dis Colon Rectum 2011;54:876-86.